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New and noteworthy 40 
Chronic obstructive pulmonary disease (COPD) patients exhibit skeletal muscle abnormalities 41 
that contribute to high fatigability. Whether muscle fatigue is sufficient to limit whole-body 42 
exercise in COPD is unknown. Unlike controls, COPD patients are simultaneously highly 43 
fatigable and have a large muscle power reserve at the limit of whole-body exercise. COPD 44 
patients are more fatigable than controls, but this fatigue is insufficient to constrain locomotor 45 
power and define the limit of tolerance. 46 
 47 
Abstract 48 
Muscle fatigue (a reduced power for a given activation) is common following exercise in 49 
COPD. Whether muscle fatigue, and reduced maximal voluntary locomotor power, are 50 
sufficient to limit whole-body exercise in COPD is unknown. We hypothesized in COPD: 51 
1) exercise is terminated with a locomotor muscle power reserve; 2) reduction in 52 
maximal locomotor power is related to ventilatory limitation; and 3) muscle fatigue at 53 
intolerance is less than age-matched controls. We used a rapid switch from hyperbolic 54 
to isokinetic cycling to measure the decline in peak isokinetic power at the limit of 55 
incremental exercise (µperformance fatigue¶) in 13 COPD (FEV1 49±17 %pred) and 12 56 
controls. By establishing the baseline relationship between muscle activity and 57 
isokinetic power, we apportioned performance fatigue into the reduction in muscle 58 
activation and muscle fatigue. Peak isokinetic power at intolerance was ~130% of peak 59 
incremental power in controls (274±73 vs 212±84W, p<0.05), but ~260% in COPD 60 
(187±141 vs 72±34W, p<0.05) ± greater than controls (p<0.05). Muscle fatigue as a 61 
fraction of baseline peak isokinetic power was not different in COPD vs controls 62 
(0.11±0.20 vs 0.19±0.11). Baseline to intolerance, the median frequency of maximal 63 
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isokinetic muscle activity was unchanged in COPD but reduced in controls (+4.3±11.6 64 
vs -5.5±7.6%, p<0.05). Performance fatigue as a fraction of peak incremental power 65 
was greater in COPD vs controls and related to resting (FEV1/FVC) and peak exercise 66 
(9ࡆ E/MVV) pulmonary function (r2=0.47, r2=0.55, p<0.05). COPD patients are more 67 
fatigable than controls, but this fatigue is insufficient to constrain locomotor power and 68 
define exercise intolerance. 69 
 70 
Abstract word count: 250 (250 max). 71 
 72 
Abbreviations 73 
AF, activation fatigue; CIDifference, 95% confidence interval of the difference; EMG, 74 
electromyography; IC, inspiratory capacity; IRV, inspiratory reserve volume; MF, muscle 75 
fatigue; MVV, maximal voluntary ventilation; PF, performance fatigue; Piso, isokinetic 76 
power  77 
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Introduction 78 
Chronic obstructive pulmonary disease (COPD) is characterized by exertional shortness 79 
of breath and exercise intolerance consequent to airflow obstruction, gas exchange 80 
abnormalities, chronic inflammation, and skeletal muscle dysfunction. Lack of regular 81 
physical activity is common in COPD (40), worsens the cycle of deconditioning and 82 
exercise intolerance, and is associated with poor quality of life, frequent hospitalizations, 83 
and high mortality (20, 50, 52). 84 
 85 
How COPD abnormalities interact to bring about the inability to maintain large-muscle-86 
mass exercise such as walking or cycling (task failure or intolerance) is of major 87 
importance, and remain poorly understood. COPD patients exhibit more exercise-88 
induced skeletal muscle fatigue (assessed by stimulated twitch force measurements) for 89 
a given absolute or normalized exercise task than age-matched controls (27, 28, 44): 90 
where WKH WHUP µfatigue¶ is defined in this paper as a loss in muscle force and/or 91 
shortening velocity that is recoverable with rest. Heightened fatigability in COPD is 92 
related to muscle capillary rarefaction, loss of oxidative capacity and reduced myofiber 93 
expression of type I myosin heavy chain (26, 45). Despite impairments in pulmonary 94 
function, many COPD patients still report leg fatigue as the major symptom limiting 95 
exercise performance (25). However, we do not know whether the reduction in available 96 
limb power (the product of average muscle force development and shortening velocity) 97 
actually defines the limit of tolerance in COPD. Do COPD patients reach limiting 98 
symptoms of breathlessness from hyperinflation (36) and low ventilatory reserve (35) 99 
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and/or leg fatigue (27, 28, 44) that are sufficient to produce a reduction in voluntary 100 
locomotor muscle power that limits performance? 101 
 102 
Measurement of muscle power and fatigue is confounded by task-specificity, the 103 
dependence of power on contraction velocity, and the rapid recovery kinetics of fatigue. 104 
The technical requirements of transcranial or peripheral nerve stimulation, interpolated 105 
twitch, or maximal voluntary contraction generally limit the measurement of fatigue to 106 
tasks evoking single-joint isometric force. Attempts to make these measurements 107 
immediately after whole-body exercise (walking or cycling) are typically delayed by ~1-108 
10 min from the point of task failure, at a time when substantial recovery has occurred 109 
(recovery half-time of ~30-60 s (10, 46)).  110 
 111 
We developed a method to measure skeletal muscle power at the limit of tolerance 112 
during cycle ergometry using an instantaneous switch from cadence-independent 113 
cycling (hyperbolic) to isokinetic (constant velocity) cycling (10). This task-specific, 114 
velocity-controlled measurement can be implemented pseudo-instantaneously at the 115 
limit of tolerance. We use brief (<5 s) maximal effort isokinetic power (Piso) 116 
measurements to quantify the total reduction, between baseline and intolerance, in 117 
voluntary isokinetic locomotor power (termed µperformance fatigue¶). As a supplemental 118 
measurement, we use surface electromyography (EMG) to measure two major 119 
components of fatigue: µactivation fatigue¶the power deficit caused by the reduction in 120 
maximal isokinetic EMG activity), and µmuscle fatigue¶the loss of isokinetic power for a 121 
given EMG activity) (10). 122 
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 123 
Using this method we aimed to determine: 1) whether COPD patients possess a 124 
reserve in locomotor power at the limit of tolerance; 2) whether declining locomotor 125 
power during exercise is related to ventilatory limitation; and 3) whether COPD patients 126 
exhibit greater proportions of the µmuscle¶ or µDFWLYDWLRQ¶ components of fatigue 127 
compared with age-matched controls. We hoped that these findings would help us to 128 
LGHQWLI\ZKHWKHUSDWLHQWVDUHXQDEOHWR µDFFHVV¶DYDLODEOH ORFRPRWRUSRZHUGXHWRWKHLU129 
cardiopulmonary symptoms and dysfunction, and if so, what mechanisms underpin their 130 
exercise intolerance.  131 
 132 
We hypothesized: 1) moderate to severe COPD patients exhibit a larger reserve in the 133 
capacity for maximal evocable power generation at the limit of tolerance than healthy 134 
age-matched controls; 2) performance fatigue in whole-body exercise in COPD is 135 
related to ventilatory limitation; and 3) COPD patients exhibit less muscle fatigue and 136 
greater activation fatigue compared to healthy controls in this large-muscle-mass 137 
exercise task. Our rationale was that pulmonary limitations in COPD constrain 138 
locomotor power through afferent feedback primarily affecting motor unit recruitment. 139 
 140 
Materials and Methods 141 
Participants 142 
Thirteen stable COPD patients (FEV1 <80% predicted; FEV1/FVC <0.7), and 12 age- 143 
and sex-matched healthy controls with normal pulmonary function provided written 144 
informed consent (Table 1). The local institutional review board approved this study, 145 
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and all procedures complied with the latest revisions of the Declaration of Helsinki and 146 
Belmont Report. All participants were screened for cardiovascular disease with a resting 147 
ECG and a medical history was taken to exclude patients with a significant disease 148 
other than COPD. Some data from 4 of the 12 age-matched controls were reported in a 149 
previous paper detailing the method of fatigue and power measurement (10). 150 
 151 
Pulmonary Function 152 
In COPD patients, post-bronchodilator (albuterol sulfate; ProAir HFA, Teva Respiratory, 153 
North Wales, PA) spirometry, body plethysmography (RV, FRC, TLC), and diffusing 154 
capacity (DLCO) measurements were performed (Vmax Encore with V62J Autobox, 155 
CareFusion, San Diego, CA) according to ATS/ERS guidelines (11, 21, 32, 33, 39). 156 
Healthy participants completed spirometry alone. Maximum voluntary ventilation (MVV) 157 
was calculated as FEV1 x 40 (33). 158 
 159 
Exercise Protocols  160 
Participants completed two experimental phases: 1) short (<5 s) bouts of variable effort 161 
isokinetic cycling at 70 rpm to determine the relationship between muscle activity (EMG) 162 
and Piso at baseline; and 2) a ramp-incremental exercise test, followed by a short (<5 s) 163 
maximal isokinetic effort at 70 rpm performed immediately at the limit of tolerance. 164 
 165 
Baseline EMG-Piso. Volunteers cycled on an ergometer (Excalibur Sport PFM, Lode, 166 
Groningen, NL) with pedaling rate constrained at 70 rpm (isokinetic). Participants gave 167 
4 variable efforts at approximately 25%, 50%, 75% and 100% of maximum. Each effort 168 
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lasted ~3-5 s, and was separated by ~1-5 min of unloaded cycling. This process was 169 
repeated 2-3 times. Baseline Piso is reported as the greatest mean power achieved over 170 
three consecutive isokinetic crank revolutions during a single repeat. 171 
 172 
EMG-Piso Following Ramp Exercise. Participants completed a ramp-incremental 173 
exercise test to the limit of tolerance (5-30 W.min-1). Ramp rate was set to 5 W.min-1 for 174 
COPD patients with FEV1 <1.0 L, 10 W.min-1 for all other COPD patients, and 15-30 175 
W.min-1IRUFRQWUROVEDVHGRQDWDUJHWUDPSGXUDWLRQRIPLQDQGSUHGLFWHG9ࡆ 22peak. 176 
During the unloaded and ramp phases, the ergometer power was cadence-independent 177 
(hyperbolic). The limit of tolerance was defined as being unable to maintain a pedaling 178 
cadence above 55 rpm, despite strong verbal encouragement. At the limit of tolerance, 179 
the ergometer was switched instantaneously to isokinetic mode at 70 rpm. As all 180 
resistance from the flywheel is removed, participants immediately accelerated pedaling 181 
cadence to the target of 70 rpm. Volunteers were strongly encouraged to give a 182 
maximal final effort for 4-5 revolutions (<5 s) before recovering at 0 W. This maneuver is 183 
similar to the baseline maximal isokinetic effort, with which the participants were well 184 
familiarized.  185 
 186 
Ergometry 187 
The computer-controlled electromagnetically-braked cycle ergometer (Excalibur Sport 188 
PFM, Lode BV, Groningen, NL) was instrumented with force transducers in the bottom 189 
bracket spindle. Left and right torque (Nm) was measured independently (peak force 190 
2000 N, < 0.5 N resolution and measurement uncertainty of < 3%). Instantaneous 191 
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angular velocity of the crank (rad.s-1) was measured with a resolution of 2° using three 192 
independent sensors sampling in series (measurement uncertainty of < 1%). During 193 
isokinetic efforts, power was calculated every 2° from torque and angular velocity 194 
measurements. There was no systematic difference in the power production between 195 
the left and right cranks. Therefore Piso was calculated from power on right crank 196 
averaged over 3 crank revolutions (5, 10), and was paired with an EMG datum from the 197 
same leg (described below). Crank power data are reported as 2 times one-leg to allow 198 
for direct comparison with power output measured at the flywheel (which, naturally, 199 
averages contributions of both legs).  200 
 201 
Electromyography 202 
Surface EMG was measured in five muscles of the right leg: vastus lateralis, rectus 203 
femoris, vastus medialis, biceps femoris, and gastrocnemius lateralis. Placement sites 204 
were shaved, abraded with gauze, and cleaned with 70%vol. isopropyl alcohol. Wireless 205 
transmitting Ag bipolar parallel-bar surface electrodes were placed over the muscle 206 
belly according to Surface Electromyography for the Non-Invasive Assessment of 207 
Muscles (SENIAM) recommendations (Trigno Wireless System, Delsys Inc., Boston, 208 
MA). Electrodes were placed over: the vastus lateralis, 2/3rds of the distance from the 209 
anterior superior iliac spine to the lateral side of the patella; the rectus femoris, halfway 210 
between the anterior superior iliac spine and the superior border of the patella; the 211 
vastus medialis, 8/10ths of the distance from the anterior superior iliac spine to the joint 212 
space in front of the anterior border of the medial ligament; the biceps femoris, halfway 213 
between the ischial tuberosity and lateral epicondyle of the tibia; and the gastrocnemius 214 
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lateralis, 1/3rd the distance between the head of the fibula and the calcaneus. The 215 
longitudinal axis of the electrode was aligned parallel to the long axis of the muscle. 216 
 217 
EMG signals were differentially amplified and sampled at 2 kHz with 16-bit resolution. 218 
Each sensor had a signal bandwidth of 20-450 Hz and common mode rejection ratio of 219 
>80 dB. During post-processing, signals were filtered with a second-order Butterworth 220 
band-pass filter (3dB, 10-500 Hz) and smoothed via root mean square (RMS) with a 221 
100 ms window. The SHDN YROWDJH ȝ9 IURP WKH  PV 506 GXULQJ HDFK FUDQN222 
revolution was used to quantify of muscle activity. The earliest three consecutive 223 
isokinetic crank revolutions that were appropriately constrained at 70 rpm were 224 
identified in the output from the cycle ergometer, and the peak RMS EMG from these 225 
were ensemble averaged for each muscle; these were typically the 2nd, 3rd, and 4th 226 
crank revolutions after switching to isokinetic cycling. The RMS EMG values from the 5 227 
muscles of the right leg were averaged to provide an EMG datum to pair with Piso 228 
produced at the crank from the same leg. Median frequency (MDF) was calculated from 229 
the same three consecutive isokinetic crank revolutions as the RMS EMG using 230 
EMGworks (Delsys Inc., Boston, MA), after first isolating the active muscle bursts from 231 
the quiescent phase of each crank revolution. The relative change in isokinetic MDF 232 
('MDF, %) between baseline and incremental peak maximal efforts were analyzed for 233 
each muscle independently and ensemble averaged. The muscle selection reflected the 234 
weighted power contributions from knee extension/flexion and plantarflexion (14). 235 
 236 
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Fatigue Characterization 237 
For characterization of the EMG-Piso relationship the RMS EMG values were normalized 238 
to the visit maximum. The baseline linear relationship between power production and 239 
EMG activity (measurement of baseline EMG-Piso) was characterized using least-240 
squares regression. Measurements made at the limit of tolerance for ramp incremental 241 
exercise were used to calculate three fatigue measurements (each expressed in W). 242 
Performance fatigue was the reduction in Piso (W) from the baseline (fatigue-free) 243 
maximum. The proportion of performance fatigue resulting from activation fatigue was 244 
calculated from the power equivalent of the reduction in RMS EMG activity, using the 245 
baseline linear regression between EMG and Piso at 70rpm. Muscle fatigue was 246 
calculated from the balance (MF = PF ± AF; with lower bounds constrained at 0 W), i.e. 247 
the deviation in power from the baseline EMG-Piso relationship at the measured EMG 248 
value (for a graphical representation for these indices, see Figure 3). Maximal isokinetic 249 
'MDF was also calculated as an independent index of muscle fatigue (31). 250 
Performance fatigue as a fraction of ramp peak power was calculated as an index of 251 
fatigue normalized for the exercise task.  252 
 253 
Cardiopulmonary Measurements 254 
Respired gases and ventilation were measured breath-by-breath with a commercial 255 
metabolic measurement system (VMax Spectra, CareFusion, San Diego, CA USA). The 256 
system was calibrated immediately prior to each testing session. A 3 L syringe (Hans 257 
Rudolph Inc., Shawnee, KS, USA) was used to calibrate the mass flow sensor from 258 
~0.2 to 8.0 L.s-1, mimicking flow rates expected at rest and during exercise. The CO2 259 
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and O2 analyzers were calibrated using gases of known concentrations (O2 26.0% and 260 
16.0%; CO2 0.0% and 4.0%). Inspiratory capacity (IC) was measured in COPD patients 261 
at rest in triplicate, and at 2 min intervals during the exercise protocol. Heart rate (HR) 262 
was measured from the 12-lead ECG (Cardiosoft, GE Healthcare, Little Chalfont, UK), 263 
and arterial O2 saturation (Masimo Corp, Irvine, CA) was monitored throughout 264 
exercise. In COPD, at rest and every 2 min during exercise, dyspnea and leg effort were 265 
assessed using the modified Borg scale (CR-10) followed by an IC maneuver.  266 
 267 
Statistical analyses 268 
Means were compared, where appropriate, with t-tests, ANOVA, or mixed model 269 
ANOVA. Statistical significance was determined at p<0.05. Data are presented as 270 
mean±SD, and, where appropriate, the 95% confidence interval of the difference 271 
(CIDifference) is included. 272 
 273 
Results 274 
At baseline, COPD patients generated a maximum Piso of 350±162 W, which was less 275 
than controls (498±160 W, p<0.05). During the ramp-incremental test, COPD patients 276 
reached a peak power (hyperbolic power measured at the flywheel) of 72±34: DQG277 
9ࡆ 22peak was 1.2±0.4 L.min-1 (Table 1). Controls produced a peak ramp power of 212±84278 
: DQG 9ࡆ 22peak was 2.6±0.9 L.min-1, which were both greater than COPD (Table 1).  279 
COPD peak Borg CR10 scores were 5.7±2.4 for leg fatigue and 5.3±2.0 for 280 
breathlessness (p=0.66). At peak ramp, inspiratory reserve volume (IRV) in COPD was 281 
0.4±0.3 L.  282 
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 283 
Comparison (group x time) of the peak power required at the end of the ramp-284 
incremental and Piso at the limit of tolerance revealed main effects of group 285 
(F[1,23]=12.4, p<0.05, Ș2=0.35) and time (F[1,23]=25.1, p<0.05, Ș2=0.52). In COPD, Piso 286 
at the limit of tolerance was ~260% of ramp peak power (187±141 vs 72±34 W, p<0.05, 287 
Figure 1C and 1D). In controls, Piso at the limit of tolerance was ~130% of ramp peak 288 
power (274±73 vs 212±84 W, p<0.05, Figure 1A and 1B). The power reserve relative to 289 
the ramp peak power was significantly greater in COPD vs controls (p<0.05). 290 
 291 
Performance fatigue as a fraction of ramp peak power was greater in COPD than CON 292 
(2.4±1.1 vs 1.1±0.3, p<0.05, Figure 2A), and in COPD was strongly and negatively 293 
related to resting (FEV1/FVC) and peak-exercise (9ࡆ E/MVV) pulmonary function (r2=0.47, 294 
r2=0.55, p<0.05, Figure 2B and 2C). In controls there were no significant relationships 295 
between performance fatigue and pulmonary function. 296 
 297 
The EMG-Piso relationship was used to characterize activation and muscle fatigue at the 298 
limit of tolerance (Figure 3). Maximum evocable EMG activity at peak was significantly 299 
greater in controls vs COPD (81.0±10.2 vs 69.4±12.2% of baseline; CIDifference 2, 21 %; 300 
p<0.05; Figure 4A). Muscle fatigue was less in COPD vs controls (30±46 vs 94±72 W, 301 
CIDifference 12, 116 W, p<0.05; Figure 4B), but was not different when expressed as a 302 
fraction of baseline peak isokinetic power (0.11±0.20 vs 0.19±0.11, p=0.3, Figure 4C). 303 
In controls, maximum effort isokinetic MDF across the 5 leg muscles fell from 77.1±17.3 304 
Hz at baseline to 72.3±16.9 Hz at peak (p<0.05). The significant decline in MDF 305 
13 
 
between baseline and peak was negatively correlated with MF in controls (r2 = 0.46, 306 
p<0.01), and the decline was greater than COPD (CIDifference 1, 19 %; p<0.05; Figure 307 
4D). In COPD, there was no change in MDF between baseline and peak (71.5±19.5 vs 308 
73.4±15.1 Hz; p>0.05). 309 
 310 
Overall, while performance fatigue was related to9ࡆ E/MVV (r2=0.24, p<0.05, Figure 5A), 311 
neither component alone of performance fatigue was correlated with 9ࡆ E/MVV (or IRV) at 312 
the limit of tolerance in COPD (Figure 5B and 5C). 313 
 314 
Discussion 315 
We aimed to determine whether the heightened muscle fatigue associated with COPD 316 
(26-28, 44, 45) limits tolerance during locomotor exercise. We found that COPD, unlike 317 
controls, were less able to voluntarily evoke maximal isokinetic muscle activity at the 318 
limit of ramp-incremental exercise, but nonetheless expressed a large reserve in short-319 
term locomotor power. Despite this instantaneous power reserve, COPD had greater 320 
performance fatigue vs controls and this was correlated with poor pulmonary function 321 
and high peak exercise 9ࡆ E/MVV. Absolute muscle fatigue was less in COPD at the limit 322 
of tolerance and maximal effort isokinetic MDF in the locomotor muscles was 323 
unchanged from baseline, unlike in controls where it was reduced. To our surprise, 324 
maximal evocable isokinetic muscle activity and activation fatigue were QRW UHODWHG WR325 
9ࡆ E/MVV in COPD.  326 
 327 
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Locomotor Power Reserve in COPD 328 
In agreement with our earlier studies (10, 16, 17), only a modest reserve in short-term 329 
skeletal muscle power production was present at the limit of tolerance in controls. Thus, 330 
the perceptual and physiological limits to exercise were closely matched. Conversely, a 331 
large skeletal muscle power reserve was present immediately following the limit of 332 
tolerance in COPD. Using a short isokinetic bout we showed that COPD patients were 333 
capable of briefly producing ~260% of the power output required at the limit of 334 
tolerance. Thus, maximal evocable power production is not the limiting factor for 335 
exercise in COPD. While the patients are unlikely to be able to sustain this power much 336 
beyond the 5 s of measurement, the power is substantially larger than the reserve in 337 
healthy young or older adults (10, 17, 34) and is consistent with a reserve in metabolic 338 
capacity of the locomotor muscles in COPD (43). While COPD patients have greater 339 
performance fatigue, they possess a short-term capacity for power production that 340 
exceeds the task requirement at the limit of tolerance ± the utility of this capacity is 341 
unknown. Without metabolic measurements of the intramuscular environment, we are 342 
unable to determine how the energy requirements are met for this brief excursion of 343 
locomotor power above the task requirement. 344 
 345 
Performance Fatigue, Pulmonary Function, and Ventilatory Limitation in COPD 346 
In controls and COPD, the Piso achieved at the limit of tolerance was approximately half 347 
of the baseline (fatigue-free) condition ± the relative decline in Piso was similar. 348 
However, as COPD patients reached a far lower peak power output in the ramp-349 
incremental task, performance fatigue as a fraction of ramp power was greater in COPD 350 
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than in controls. In other words, COPD patients had a greater fatigability than controls. 351 
This is consistent with substantial locomotor fatigue reported previously in COPD (2, 27, 352 
28, 44). The important distinction in our data is that maximal evocable power remained 353 
well in excess of the power output required by the task at intolerance.  354 
 355 
Skeletal muscle weakness, atrophy, loss of oxidative capacity, and increased fatigability 356 
are serious problems in COPD (12, 29). We found that baseline Piso was ~29% lower in 357 
COPD, likely reflecting the loss of muscle mass and fibrotic and fat muscle infiltration in 358 
patients (29). However, the limit of tolerance is more likely defined by dyspnea arising 359 
from ventilatory limitation, hyperinflation or increased respiratory muscle work rather 360 
than an inability of the atrophied locomotor muscles to produce the power required by 361 
the task (18, 22, 43). Therefore, while performance fatigue during cycling appears to 362 
elicit a large contribution from central mechanisms limiting power production in both 363 
COPD and controls (48), task failure in controls appears to be associated with a greater 364 
contribution from a muscle fatigue-induced reduction in locomotor power (10, 17), cf. 365 
(34). 366 
 367 
Performance fatigue in COPD was strongly related to pulmonary function and an index 368 
of ventilatory limitation; the patients with the lowest FEV1/FVC and greatest 9ࡆ E/MVV 369 
showed the greatest fatigue (Figure 2). Feedback to the motor cortex from 370 
hyperinflation, increased accessory muscle work, or some other mechanism related to 371 
ventilatory limitation or dyspnea, may reduce motor cortex excitability and therefore limit 372 
evocable muscle activity and power production. This may be a mechanism by which the 373 
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FRPPRQ V\PSWRP RI ³OHJ IDWLJXH´ occurs in COPD patients. That is, not as a direct 374 
consequence of muscle fatigue from disruption of cross-bridge cycling, but via inhibition 375 
of central motor drive that requires, and is perceived as, an increased effort to drive 376 
locomotor muscles to maintain the task. Interestingly, pulmonary C-fiber receptors were 377 
originally hypothesized to contribute to the termination of high-intensity exercise in a 378 
similar CNS feedback-dependent manner (38). However, this mechanism remains 379 
highly controversial (51). In humans, for example, stimulation of the pulmonary C-fibers 380 
with intravenous lobeline increased the size of the H-reflex, magnified the EMG 381 
responses to transcranial magnetic stimulation, and did not inhibit voluntary force 382 
production (19). Thus, while the structures and mechanisms are not well-understood, it 383 
is very likely that flow limitation, high work of breathing, abnormal lung mechanics, and 384 
dyspnea conspire to reduce voluntary motor activity via negative feedback to the CNS 385 
(see (36)). 386 
 387 
We want to emphasize that while locomotor power did not constrain the completion of 388 
the task per se, skeletal muscle deconditioning and/or dysfunction in COPD is a major 389 
contributor to poor quality of life, morbidity, and mortality. Firstly, absolute muscle power 390 
is lower in COPD vs healthy controls. Second, greater reliance on non-oxidative 391 
metabolism results in elevated ventilatory demands (6). Therefore, skeletal muscle 392 
contributes to bringing about task failure through taxing an already-challenged 393 
ventilatory system (29, 49), even though maximal evocable power does not fall to meet 394 
the task requirement in the way it does for healthy individuals. Thus, we wish to make it 395 
clear that our findings are not evidence to weaken the rationale and need for physical 396 
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rehabilitation in COPD. On the contrary, we feel that our data strengthen the rationale 397 
for rehabilitation. There is little doubt that rehabilitation reduces fatigability, contributes 398 
to improved quality of life, and reduces exacerbations and hospitalizations (3). Even 399 
with a large power reserve at the limit of tolerance, the absolute power eliciting 400 
intolerance in COPD was still far lower than controls, and a heightened fatigue appears 401 
to contribute to limiting performance (1). The consequences of a low maximal evocable 402 
power (whether fresh or fatigued) are devastatingly clear for a patient who cannot rise 403 
from a chair or climb a flight of stairs.  404 
 405 
Skeletal Muscle Fatigue in COPD Patients and Controls 406 
Due to the large differences in power between COPD and controls, more absolute 407 
muscle fatigue was present in controls. Consistent with this, unlike controls, there was 408 
no decline in MDF of maximal voluntary isokinetic power production at intolerance in 409 
COPD patients; a reduction in MDF is associated with muscle acidosis, muscle lactate 410 
accumulation (48) and fatigue (31). However, when normalized to a fraction of baseline 411 
Piso, muscle fatigue was not different between patients and controls. While there is a 412 
small numerical difference between the normalized muscle fatigue of COPD and 413 
controls (Figure 4C), it is the heterogeneity of the responses that is most interesting, 414 
particularly the patients with no muscle fatigue. The wide variance in muscle fatigue for 415 
COPD patients is consistent with other reports in the literature, as is the presence of 416 
what might be a small subset of patients who fail to develop muscle fatigue during 417 
heavy cycle ergometry (2, 4). None of our measures for pulmonary function or disease 418 
severity explained the heterogeneity in muscle fatigue. This reinforces the common 419 
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finding that muscle dysfunction and exercise intolerance are only weakly or moderately 420 
correlated to standard measures of spirometric impairment in COPD (23, 37), despite 421 
being independent risk factors for poor outcome in population studies.  422 
 423 
Where development of muscle fatigue is prevented due to a ceiling imposed by disease 424 
symptoms, the patients may possess a reserve of muscle power that they are unable to 425 
access. For example, after improvement in time to limitation with spinal anesthesia, 426 
COPD patients exhibited greater peripheral muscle fatigue 10 minutes after the limit of 427 
tolerance, measured by potentiated quadriceps twitch force (18). In this case, it appears 428 
as though a lower ventilatory demand with spinal anesthesia revealed an ability to 429 
access the metabolic and locomotor muscle power reserve (18, 22, 43). The hyperbolic-430 
to-isokinetic switch, at limit of tolerance, is a non-invasive alternative to quantify this 431 
reserve in metabolism and power instantaneously at the point of limitation.  432 
 433 
Activation Fatigue and Ventilatory Limitation 434 
High 9ࡆ E/MVV was not related to activation fatigue at the limit of tolerance, and tended to 435 
relate to maximal evocable isokinetic muscle activity (r2=0.26; p=0.07). However, the 436 
perceptions of effort and dyspnea are non-linear as a function of the WDVN¶Vdemands 437 
and operating lung volumes (24, 36). Steep increasesLQV\PSWRPVDERYH9ࡆ E/MVV 0.8-438 
0.9 and wide variance in 9ࡆ E/MVV at peak exercise in our cohort PD\KDYHFRQIRXQGHG439 
WKHUHODWLRQVKLSEHWZHHQ9ࡆ E/MVV and activation fatigue (Figure 5B). ,Q OLJKWRI WKLVZH440 
H[DPLQHG  SDWLHQWV ZLWK 9ࡆ E/MVV >0.9, and found worse pulmonary function, 441 
exacerbated performance fatigue, and a tendency (p  IRUDFWLYDWLRQ IDWLJXH WREH442 
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JUHDWHU FRPSDUHG WR SDWLHQWV ZLWK 9ࡆ E/MVV <0.9. Further work is clearly required to 443 
determine whether central limitation to muscle activation is sensitive to the 444 
encroachment of ventilatory limits, hyperinflation, accessory muscle work of breathing, 445 
or other factors related to dyspnea that may reduce cortical motor excitability and limit 446 
locomotor power. 447 
 448 
Future Directions and Limitations 449 
Our next step is to examine how effective interventions (7, 9, 30, 41, 47) for dyspnea 450 
and exercise tolerance affect the rate and magnitude of performance fatigue and its 451 
components. Whether effective interventions such as rehabilitation, HeO2 breathing, or 452 
supplemental O2 allow access to a reserve in skeletal muscle power by alleviating 453 
dyspnea, or by retarding the dynamics of skeletal muscle fatigue (or a combination of 454 
the two) is unknown. 455 
 456 
A limitation in our study is that we did not incorporate a method to separate activation 457 
and muscle fatigue using a defined external stimulus (e.g. by muscle or nerve 458 
stimulation). The experimental approach used simply quantifies the combination of 459 
activation fatigue and muscle fatigue that sums to determine peak power output at the 460 
point of limitation, under whatever level of motor activity that can be achieved by a 461 
maximum voluntary effort. Therefore, it assesses the maximal voluntary performance, 462 
and not the instantaneous capacity of the central nervous and muscular systems. The 463 
relative contributions of baseline muscle weakness, capillary rarefaction, fiber type shift, 464 
reduced muscle oxidative capacity, and other muscle abnormalities that contribute to 465 
20 
 
influence both central and peripheral components and fatigability in COPD are not 466 
determined. Similarly, our secondary indices of fatigue are reliant on surface EMG ± an 467 
indirect assessment of muscle activity, by its nature. We do not know how the patterns 468 
of activity change during the exercise bout (as this was not velocity constrained), and 469 
whether this history of muscle activation changes the interpretation of our maximal-effort 470 
isokinetic measurements. However, it is unlikely that the differences in EMG amplitude 471 
between patients and controls are due to amplitude cancellation (13) or motor unit 472 
synchronization (15). It is less clear whether differences in the common input to the 473 
motor unit pool can explain the reduced maximal evocable EMG activity at intolerance 474 
in COPD (8). 475 
 476 
Summary 477 
We applied a new experimental approach with instantaneous switching between 478 
hyperbolic and isokinetic cycle ergometry to identify whether locomotor fatigue limits 479 
whole-body exercise and aerobic capacity in COPD patients. We found, both at 480 
baseline and immediately following intolerance of ramp-incremental cycling, isokinetic 481 
power was lower in COPD patients compared with age-matched healthy controls. In 482 
COPD, performance fatigue was negatively correlated with resting pulmonary function 483 
(FEV1/FVC) and positively correlated with exercise ventilatoU\ OLPLWDWLRQ 9ࡆ E/MVV). In 484 
addition, the relative loss of locomotor power was ~2.4 times greater in COPD patients 485 
compared with controls. Despite this heightened fatigue, COPD patients, unlike 486 
controls, possessed a large reserve in maximal evocable isokinetic power at the 487 
tolerable limit (~2.6 times peak ramp power). As such, substantial fatigue is present in 488 
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COPD and associated with a significantly lesser ability to activate locomotor muscles 489 
compared to age-matched controls. However, this fatigue is not sufficient to constrain 490 
locomotor power and define the tolerable limit of whole-body exercise.  491 
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 505 
Figure 1. Representative participant data and group data for power production during 506 
ramp-incremental and maximal isokinetic cycling. The dotted lines indicate that data are 507 
continuous: the x-axis is expanded at the end of the ramp-incremental to better show 508 
the power output during the brief (<5 s) maximal isokinetic effort (black shading on x-509 
axis). Grey shading along the x-axis represents hyperbolic ergometry (cadence 510 
independent power). Black shading along the x-axis represents maximal isokinetic 511 
cycling at 70 rpm. Panel A: Mean right crankarm power from a representative healthy 512 
control. Panel B: Group data from healthy controls comparing peak power achieved 513 
during ramp-incremental and isokinetic phases. Isokinetic refers to the brief (<5 s) 514 
maximal effort immediately following the limit of tolerance. Panel C: Mean right 515 
crankarm power from a representative COPD patient. Panel D: Group data from COPD 516 
patients comparing peak power achieved during ramp-incremental and isokinetic 517 
phases. *Different (p<0.05) from ramp-incremental peak power.  518 
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 519 
 520 
Figure 2. Performance fatigue during ramp-incremental exercise in COPD and controls. 521 
Panel A: Performance fatigue as a fraction of peak ramp power was significantly 522 
greater in COPD. *Different from CON (p<0.05) Panel B: Performance fatigue was 523 
strongly related to FEV1/FVC in COPD (p<0.05), but there was no significant 524 
relationship in CON (data not shown). Panel C: Performance fatigue ZDV VWURQJO\525 
UHODWHG WR9ࡆ E/MVV in COPD (p<0.05) but there was no significant relationship in CON 526 
(data not shown).  527 
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 528 
Figure 3. The relationship between EMG activity and isokinetic power (Piso) in 529 
representative COPD and control participants. The data includes the baseline (fatigue-530 
free) measurements (Ɣ) and the maximal effort measurement at the limit of tolerance 531 
ż $OO PHDVXUHPHQWV ZHUH WDNHQ DW  USP Performance fatigue (PF) arrow 532 
represents the total reduction in power generation immediately at the limit of ramp-533 
incremental exercise. Activation fatigue (AF) represents the proportion of performance 534 
fatigue resulting from a reduced maximal evocable muscle activity. Muscle fatigue (MF) 535 
arrow represents the proportion of performance fatigue that can be attributed to muscle 536 
fatigue i.e. a lower power than expected for the measured EMG. Panel A: 537 
Representative control participant showing large muscle fatigue component (as a 538 
fraction of the performance fatigue). Panel B: Representative COPD participant 539 
showing no muscle fatigue component. 540 
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 541 
Figure 4. Maximal isokinetic muscle activity and fatigue at the limit of tolerance in 542 
COPD and controls. Panel A: Maximal evocable isokinetic muscle activity (RMS EMG) 543 
as a percentage of baseline ('EMG). *Difference between groups (CIDifference 2, 21 %, 544 
p<0.05). Panel B: Muscle fatigue (MF). *Difference between groups (CIDifference 12, 116 545 
W, p<0.05). Panel C: Muscle fatigue (MF) expressed as a fraction of the baseline 546 
maximal isokinetic power (BL Piso). Two groups not significantly different (CIDifference  -10, 547 
40%, p>0.05). Panel D: The relative change in in median frequency of isokinetic EMG 548 
activity between baseline and peak ('MDF). *Difference between groups (CIDifference 1, 549 
19 %, p<0.05). 550 
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 551 
Figure 5. Relationship between 9ࡆ E/MVV and fatigue components in COPD patients. 552 
Panel A: Performance fatigue (PF)SORWWHGDVDIXQFWLRQRI9ࡆ E/MVV (r2=0.24, p<0.05). 553 
Panel B: Muscle fatigue (MF) plotted as a function of 9ࡆ E/MVV (r2=0.1, p>0.05). Panel 554 
C: Activation fatigue (AF) plotted as a function of 9ࡆ E/MVV (r2=0.1, p>0.05).  555 
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Table 1. Patient characteristics at rest and peak exercise 556 
 Control COPD p-value 
N (m/f) 12 (10/2) 13 (11/2) -- 
 
   
Characteristics 
   
Age, yr 65 ± 9 65 ± 11 0.96 
Height, cm 172 ± 8 169 ± 7 0.28 
Weight, kg 79 ± 13 70 ± 13 0.09 
BMI, kg/m2 26.8 ± 3.4 24.5 ± 4.1 0.15 
Resting SpO2, % 97 ± 1 99 ± 1 0.04 
 
   
Pulmonary Function 
   
FEV1, L 3.1 ± 0.7 1.4 ± 0.6 <0.01 
FEV1, % predicted  107 ± 16 49 ± 17 <0.01 
FEV1/FVC, %  75 ± 10 40 ± 11 <0.01 
GOLD spirometric class, 2/3/4 -- 4/8/1 -- 
RV, L -- 2.78 ± 0.65 -- 
RV, % predicted -- 120 ± 13 -- 
FRC, L -- 4.11 ± 0.74 -- 
FRC, %predicted -- 124 ± 26 -- 
TLC, L -- 5.96 ± 0.98 -- 
TLC, % predicted -- 97 ± 17 -- 
RV/TLC -- 0.47 ± 0.09 -- 
DLCO, ml.min-1.mm Hg-1 -- 10.5 ± 4.1 -- 
DLCO, % predicted -- 42 ± 12 -- 
IC, L -- 2.2 ± 0.7 -- 
 
   
Ramp-Incremental Exercise 
   
Peak power, W 212 ± 84 72 ± 34 <0.01 
9ࡆ 22peak, L.min-1 2.6 ± 0.9 1.2 ± 0.4 <0.01 
9ࡆ 22peak, mL.min-1.kg-1 32.2 ± 8.3 17.1 ± 5.7 <0.01 
Peak HR, min-1 147 ± 39 117 ± 17 0.13 
3HDN9ࡆ E, L.min-1 112 ± 34 47 ± 16 <0.01 
3HDN9ࡆ E/MVV, % 81 ± 19 86 ± 14 <0.01 
Peak SpO2, % 96 ± 3 95 ± 4 0.70 
Peak IC, L -- 1.9 ± 0.6 -- 
Peak IRV, L -- 0.4 ± 0.3 -- 
Definition of abbreviations: BMI, body mass index; DLCO, lung diffusion capacity; FEV1, 557 
forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced 558 
vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, heart 559 
rate; IC, inspiratory capacity, IRV, inspiratory reserve volume; MVV, maximal voluntary 560 
ventilation; RV, residual volume; SpO2R[\JHQVDWXUDWLRQE\SXOVHR[LPHWU\7/&WRWDO561 
OXQJ FDSDFLW\ 9ࡆ E YHQWLODWLRQ 9ࡆ 22, oxygen uptake. Data are mean ± SD. Prediction 562 
equations used: (21, 42)  563 
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